

## SUPPLEMENTARY MATERIAL

*Additional references for the sections on pathogenesis, biomarkers, treatment and then each table are listed below.*

### Pathogenesis

Human Gene Mutation Database version 2018.2. [www.hgmd.cf.ac.uk](http://www.hgmd.cf.ac.uk) (accessed December 2019).

Litwin T, Gromadzka G, Członkowska A. Apolipoprotein E gene (APOE) genotype in Wilson's disease; Impact on clinical presentation. *Parkinsonism Relat Dis.* 2012;18:367-369.

Meenakshi-Sundaram S, Mahadevan A, Taly AB, *et al.* Wilson's disease: a clinico-neuropathological autopsy study. *J Clin Neurosci* 2008;15(4):409-17.

Stern G. Die Pathoklise [Parkinson's disease]. *J Neural Transm Suppl* 1993;40:93-9.

Bruehlmeier M, Leenders KL, Vontobel P, *et al.* Increased cerebral iron uptake in Wilson's disease: a <sup>52</sup>Fe-citrate PET study. *J Nucl Med* 2000;41(5):781-7.

### Biomarkers

Poujois A, Woimant F. Chapter 10 - Biochemical Markers. In: Weiss KH, Schilsky M, eds. *Wilson Disease*. Academic Press; 2019:115-124.

Trocello JM, El Balkhi S, Woimant F, *et al.* Relative exchangeable copper: a promising tool for family screening in Wilson disease. *Mov Disord* 2014;29(4):558-62.

Guillaud O, Brunet AS, Mallet I, *et al.* Relative exchangeable copper: A valuable tool for the diagnosis of Wilson disease. *Liver Int* 2018;38(2):350-357.

Barbosa ER, Caramelli P, Bacheschi LA, *et al.* Wilson's disease: magnetic resonance imaging (MRI) with clinical correlations in 16 cases. *Rev Paul Med* 1993;111(3):407-11.

Starosta-Rubinstein S, Young AB, Kluin K, *et al.* Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. *Arch Neurol* 1987;44(4):365-70.

Magalhaes AC, Caramelli P, Menezes JR, *et al.* Wilson's disease: MRI with clinical correlation. *Neuroradiology* 1994;36(2):97-100.

Oder W, Prayer L, Grimm G, *et al.* Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. *Neurology* 1993;43(1):120-4.  
EASL. EASL Clinical Practice Guidelines: Wilson's disease. *J Hepatol* 2012;56(3):671-85.

Ryan A, Nevitt SJ, Tuohy O, *et al.* Biomarkers for diagnosis of Wilson's disease. *Cochrane Database Syst Rev* 2019;2019(11).

Seniów J, Bąk T, Gajda J, *et al.* Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. *Mov Dis* 2002;17(5):1077–1083.

Leśniak M, Członkowska A, Seniów J, Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson' disease. *Mov Dis* 2008;23(14):2067–2073.

### Treatments

Członkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. *J Neurol* 1996;243(3):269-73.

Weiss KH, Thurik F, Gotthardt DN, *et al.* Efficacy and safety of oral chelators in treatment of patients with Wilson disease. *Clin Gastroenterol Hepatol* 2013;11(8):1028-35 e1-2.

### Table 1

Członkowska A, Litwin T, Dziezyc K, *et al.* Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale. *BMC Neurol* 2018;18(1):34.

Machado A, Chien HF, Deguti MM, *et al.* Neurological manifestations in Wilson's disease: Report of 119 cases. *Mov Disord* 2006;21(12):2192-6.

Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. *J Neurol Neurosurg Psychiatry* 1992;55(8):692-6.

Dening TR, Berrios GE. Wilson's disease. Psychiatric symptoms in 195 cases. *Arch Gen Psychiatry* 1989;46(12):1126-34.

Svetel M, Potrebic A, Pekmezovic T, *et al.* Neuropsychiatric aspects of treated Wilson's disease. *Parkinsonism Relat Disord* 2009;15(10):772-5.

Zimbrea PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. *Gen Hosp Psychiatry* 2014;36(1):53-62.

Przybyłkowski A, Gromadzka G, Chabik G, *et al.* Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. *Funct Neurol* 2014;29(1):23-9.

### Table 2

#### *T1-weighted (structural) imaging*

Stein A, George L, Jhunjhunwala K, *et al.* Exploring cortical atrophy and its clinical and biochemical correlates in Wilson's disease using voxel based morphometry. *Parkinsonism Relat Disord* 2016;30:52-7.

Smolinski L, Litwin T, Redzia-Ogrodnik B, *et al.* Brain volume is related to neurological impairment and to copper overload in Wilson's disease. *Neurol Sci* 2019;40(10):2089-2095.

Zou L, Song Y, Zhou X, *et al.* Regional morphometric abnormalities and clinical relevance in Wilson's disease. *Mov Disord* 2019;34(4):545-554.

Song Y, Zou L, Zhao J, *et al.* Whole brain volume and cortical thickness abnormalities in Wilson's disease: a clinical correlation study. *Brain Imaging Behav* 2020.

Tinaz S, Arora J, Nalamada K, *et al.* Structural and functional brain changes in hepatic and neurological Wilson disease. *Brain Imaging Behav* 2020.

Viveiros A, Beliveau V, Panzer M, *et al.* Neurodegeneration in Hepatic and Neurologic Wilson Disease. *Hepatology* 2020.

Hu S, Xu C, Dong T, *et al.* Structural and Functional Changes Are Related to Cognitive Status in Wilson's Disease. *Front Hum Neurosci* 2021;15:610947.

Dusek P, Lescinskij A, Ruzicka F, *et al.* Associations of Brain Atrophy and Cerebral Iron Accumulation at MRI with Clinical Severity in Wilson Disease. *Radiology* 2021:202846.

#### *Susceptibility-weighted imaging*

Fritsch D, Reiss-Zimmermann M, Trampel R, *et al.* Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. *Invest Radiol* 2014;49(5):299-306.

Bai X, Wang G, Wu L, *et al.* Deep-gray nuclei susceptibility-weighted imaging filtered phase shift in patients with Wilson's disease. *Pediatr Res* 2014;75(3):436-42.

Zhou XX, Qin HL, Li XH, *et al.* Characterizing brain mineral deposition in patients with Wilson disease using susceptibility-weighted imaging. *Neurol India* 2014;62(4):362-6.

Yang J, Li X, Yang R, *et al.* Susceptibility-Weighted Imaging Manifestations in the Brain of Wilson's Disease Patients. *PLoS One* 2015;10(4):e0125100.

Dezortova M, Lescinskij A, Dusek P, *et al.* Multiparametric Quantitative Brain MRI in Neurological and Hepatic Forms of Wilson's Disease. *J Magn Reson Imaging* 2020;51(6):1829-1835.

Dusek P, Lescinskij A, Ruzicka F, *et al.* Associations of Brain Atrophy and Cerebral Iron Accumulation at MRI with Clinical Severity in Wilson Disease. *Radiology* 2021:202846.

#### *Diffusion-weighted imaging*

Jadav R, Saini J, Sinha S, *et al.* Diffusion tensor imaging (DTI) and its clinical correlates in drug naive Wilson's disease. *Metab Brain Dis* 2013;28(3):455-62.

Lawrence A, Saini J, Sinha S, *et al.* Improvement of Diffusion Tensor Imaging (DTI) Parameters with Decoppering Treatment in Wilson's Disease. *JIMD Rep* 2016;25:31-37.

Zhou XX, Li XH, Qin H, *et al.* Diffusion tensor imaging of the extracortical network in the brains of patients with Wilson disease. *J Neurol Sci* 2016;362:292-8.

Wang A, Wu H, Xu C, *et al.* Study on Lesion Assessment of Cerebello-Thalamo-Cortical Network in Wilson's Disease with Diffusion Tensor Imaging. *Neural Plast* 2017;2017:7323121.

Song YK, Li XB, Huang XL, *et al.* A study of neurite orientation dispersion and density imaging in wilson's disease. *J Magn Reson Imaging* 2018;48(2):423-430.

Dong T, Yang WM, Wu MC, *et al.* Microstructure changes in whiter matter relate to cognitive impairment in Wilson's disease. *Biosci Rep* 2019;39(3)

Hu S, Xu C, Dong T, *et al.* Structural and Functional Changes Are Related to Cognitive Status in Wilson's Disease. *Front Hum Neurosci* 2021;15:610947.

### Table 3

#### *Magnetic resonance spectroscopy*

Van Den Heuvel AG, Van der Grond J, Van Rooij LG, *et al.* Differentiation between portal-systemic encephalopathy and neurodegenerative disorders in patients with Wilson disease: H-1 MR spectroscopy. *Radiology* 1997;203(2):539-43.

Kraft E, Trenkwalder C, Then Bergh F, *et al.* Magnetic resonance proton spectroscopy of the brain in Wilson's disease. *J Neurol* 1999;246(8):693-9.

Lucato LT, Otaduy MC, Barbosa ER, *et al.* Proton MR spectroscopy in Wilson disease: analysis of 36 cases. *AJNR Am J Neuroradiol* 2005;26(5):1066-71.

Tarnacka B, Szeszkowski W, Golebiowski M, *et al.* Metabolic changes in 37 newly diagnosed Wilson's disease patients assessed by magnetic resonance spectroscopy. *Parkinsonism Relat Disord* 2009;15(8):582-6.

Tarnacka B, Szeszkowski W, Golebiowski M, *et al.* MR spectroscopy in monitoring the treatment of Wilson's disease patients. *Mov Disord* 2008;23(11):1560-6.

Tarnacka B, Szeszkowski W, Buettner J, *et al.* Heterozygous carriers for Wilson's disease--magnetic spectroscopy changes in the brain. *Metab Brain Dis* 2009;24(3):463-8.

Pulai S, Biswas A, Roy A, *et al.* Clinical features, MRI brain, and MRS abnormalities of drug-naive neurologic Wilson's disease. *Neurol India* 2014;62(2):153-8.

Alkhalik Basha MA, Refaat R, Ahmed AF, *et al.* Brain magnetic resonance spectroscopy (MRS) as a diagnostic tool for detecting early neurological changes in children with Wilson's disease. *Eur J Radiol* 2019;111:41-46.

#### *Single photon emission computed tomography*

Barthel H, Sorger D, Kuhn HJ, *et al.* Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [<sup>123</sup>I]ss-CIT and high-resolution SPET. *Eur J Nucl Med* 2001;28(11):1656-63.

Hermann W, Eggers B, Barthel H, *et al.* Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. *J Neurol* 2002;249(8):1082-7.

Eggers B, Hermann W, Barthel H, *et al.* The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson's disease. *J Neurol* 2003;250(5):576-80.

Wang P, Hu P, Yue DC, *et al.* The clinical value of Tc-99m TRODAT-1 SPECT for evaluating disease severity in young patients with symptomatic and asymptomatic Wilson disease. *Clin Nucl Med* 2007;32(11):844-9.

Piga M, Murru A, Satta L, *et al.* Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease. *Eur J Nucl Med Mol Imaging* 2008;35(4):716-24.

Eo JS, Lee HY, Lee JS, *et al.* Automated Analysis of (123)I-beta-CIT SPECT Images with Statistical Probabilistic Anatomical Mapping. *Nucl Med Mol Imaging* 2014;48(1):47-54.

#### *Transcranial sonography*

Walter U, Krolkowski K, Tarnacka B, *et al.* Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. *Neurology* 2005;64(10):1726-32.

Svetel M, Mijajlović M, Tomić A, *et al.* Transcranial sonography in Wilson's disease. *Parkinsonism Relat Disord* 2012;18(3):234-8.

Maskova J, Skoloudik D, Burgetova A, *et al.* Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases. *Parkinsonism Relat Disord* 2016;28:87-93.

Tribl GG, Trindade MC, Almeida KJ, *et al.* Quantitative transcranial sonography in Wilson's disease and healthy controls: Cut-off values and functional correlates. *J Neurol Sci* 2018;385:69-74.

Skowronska M, Litwin T, Kurkowska-Jastrzebska I, *et al.* Transcranial sonography changes in patients with Wilson's Disease during de-coppering therapy. *Neurol Neurochir Pol* 2020;54(2):185-192.

Skowronska M, Litwin T, Kurkowska-Jastrzebska I, *et al.* Transcranial sonography changes in heterozygotic carriers of the ATP7B gene. *Neurol Sci* 2020;41(9):2605-2612.

Skoloudik D, Maskova J, Dusek P, *et al.* Digitized Image Analysis of Insula Echogenicity Detected by TCS-MR Fusion Imaging in Wilson's and Early-Onset Parkinson's Diseases. *Ultrasound Med Biol* 2020;46(3):842-848.